Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View


Intersect ENT: Real-world Data Support Use Of PROPEL In


RTTNews | Jan 25, 2022 07:41AM EST

07:40 Tuesday, January 25, 2022 (RTTNews.com) - Intersect ENT, Inc. (XENT) reported positive results of an observational, cohort study using real-world evidence data from adult patients with chronic rhinosinusitis with or without nasal polyps who underwent endoscopic sinus surgery. The company said the results showed that patients receiving PROPEL sinus implants following sinus surgery had lower healthcare resource utilization over a postoperative period of 18 months compared with patients who did not receive an implant.

"We intend to incorporate these findings into our ongoing discussions with payers as we strive to increase patient and physician access to PROPEL in appropriate populations," said Thomas West, CEO of Intersect ENT.

Read the original article on RTTNews ( https://www.rttnews.com/3257025/intersect-ent-real-world-data-support-use-of-propel-in-patients-undergoing-endoscopic-sinus-surgery.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2022 RTTNews.com All Rights Reserved






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC